Histamine News and Research

RSS

Histamine is a biogenic amine chemical involved in local immune responses as well as regulating physiological function in the gut and acting as a neurotransmitter.

FDA approves ISTA's Bepreve for treating ocular itch

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the U.S. Food and Drug Administration (FDA) has approved Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis in patients two years of age and older.

9 Sep 2009

Two 2008 drug approval reports highlight Ceplene benefits

EpiCept Corporation today announced that Ceplene (histamine dihydrochloride) has been highlighted in two separate reports issued recently reviewing 2008 drug approvals in the European Union.

3 Sep 2009

Herbalscience research throws light on causes of allergic rhinitis

Most people might think of nettle as simply a common and aggressive weed that can sting and cause skin irritation. But nettle has also been used for hundreds of years to treat seasonal allergies and other inflammatory diseases, although the precise nature of its anti-inflammatory effect was unknown. Now, scientists with HerbalScience have identified specific bioactives in nettle leaf extracts that inhibit in vitro receptors and enzymes known to be key in generating symptoms of allergic rhinitis, or hay fever.

26 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

Neurogen stockholders to receive $11 million in Ligand Pharmaceuticals common stock as part of acquisition deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and Neurogen Corporation (NASDAQ:NRGN) announced today they have entered into a definitive merger agreement under which Ligand will acquire Neurogen. Under the transaction, Neurogen stockholders will receive an estimated $11 million in Ligand common stock and will be granted Contingent Value Rights (“CVRs”) under four CVR agreements.

25 Aug 2009

Epicept files NDA for Ceplene in Canada

EpiCept Corporation has announced that it has filed a New Drug Submission (NDS) with Health Canada for Ceplene® (histamine dihydrochloride) for the treatment of acute myeloid leukemia (AML) patients in first complete remission. Health Canada typically accepts or refuses an NDS and designates review status within forty-five days of filing. If accepted, the customary timeframe for completion of review and an approval decision is within one year.

5 Aug 2009

Histamine affects alcohol-related behaviour

The histamine-3 receptor is important in terms of alcohol-related behaviour, and a drug affecting that receptor may have qualities that alter alcohol-related behaviour.

16 Jun 2009

Sublingual immunotherapy for inhalant allergies deserves deeper consideration

Sublingual immunotherapy for the treatment of allergy symptoms caused by a wide variety of environmental inhalants has been effectively used in Europe.

30 Apr 2009

Poor sleep disturbs neuroendocrine control of appetite

Laboratory and epidemiological studies continue to show that sleep curtailment and/or decreased sleep quality can disturb neuroendocrine control of appetite, leading to overeating, and can decrease insulin and/or increase insulin resistance, both steps on the road to Type 2 diabetes.

22 Apr 2009

Scientists mine drugs database for new diabetes treatment

Scientists funded by the Biotechnology and Biological Sciences Research Council have harnessed a new drug discovery tool to identify a new player in the body's insulin secretion process.

22 Feb 2009

New mouse model for peanut allergy

Chicago researchers report the development of a new mouse model for food allergy that mimics symptoms generated during a human allergic reaction to peanuts.

12 Jan 2009

Pain and itch regulated by different molecular mechanisms

Historically, scientists have regarded itching as a less intense version of the body's response to pain, but researchers at Washington University School of Medicine in St. Louis have determined that pain and itch actually are regulated by different molecular mechanisms.

17 Nov 2008

In mice, anxiety is linked to immune system

In the first study ever to genetically link the immune system to normal behavior, scientists at Rockefeller and Columbia universities show that mast cells, known as the pharmacologic bombshells of the immune system, directly influence how mice respond to stressful situations.

27 Oct 2008

Luna awarded NIH grant for fullerene-based nanomedicines as allergy treatments

Luna Innovations Incorporated has announced the award of a $1.6 million Research Project Grant (R01) from the National Institutes of Health (NIH) to investigate the use of fullerene-based nanomedicines as a pathway to treat allergies and other inflammatory diseases.

22 Jul 2008

Probiotics provide hay fever hope

With the peak grass pollen season approaching, scientists can reveal that a daily dose of probiotic can change the immune status of people with hay fever.

2 Jun 2008

ISTA Pharmaceuticals announces new clinical findings to support Bepreve NDA

ISTA Pharmaceuticals, Inc. has announced positive results from the preliminary analysis of its second and final Bepreve (bepotastine ophthalmic solution) Phase III clinical study.

30 Apr 2008

EpiCept announces opinion by European Regulatory Authority on Ceplene

EpiCept Corporation has announced that the European Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has issued, as expected following the trend vote announced last month, a negative opinion regarding the marketing authorization application (MAA) for Ceplene (histamine dihydrochloride) for the remission maintenance and prevention of relapse of patients with Acute Myeloid Leukemia (AML) in first remission.

24 Mar 2008

Clearer understanding on how allergy symptoms are triggered

A team of Penn State University researchers is the first to demonstrate that lipid molecules in cell membranes participate in mammals' reactions to allergens in a living cell.

10 Mar 2008

How asthma and allergy symptoms are triggered

In demonstrating that a group of calcium ion channels play a crucial role in triggering inflammatory responses, researchers at Beth Israel Deaconess Medical Center (BIDMC) have not only solved a longstanding molecular mystery regarding the onset of asthma and allergy symptoms, but have also provided a fundamental discovery regarding the functioning of mast cells.

15 Jan 2008

Protein a possible key to allergy and asthma control

Activating a protein found on some immune cells seems to halt the cells' typical job of spewing out substances that launch allergic reactions, a study by Johns Hopkins researchers suggests.

3 Jan 2008